Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101654 | 0.88 | ATR (0.53) | HRH4KDM4ESMG1CSNK1DMAPK14 | |
| SCHEMBL4096378 | 0.84 | ATR (0.53) | HRH4HTR3AMTORMETADORA2A | |
| SCHEMBL4102195 | 0.84 | HRH4 (0.45) | HRH4HTR3AKDM4ERAD52UBE2N | |
| SCHEMBL4102137 | 0.83 | CKS1B (0.54) | ADORA2A | |
| SCHEMBL4107779 | 0.81 | DHFR (0.44) | HRH4HTR3AKDM4ERAD52UBE2N | |
| SCHEMBL4104424 | 0.77 | ADORA2A (0.57) | KDM4EADORA2AADORA1 | |
| SCHEMBL4102329 | 0.77 | ALDH1A1 (0.59) | KDM4EL3MBTL1MTORADORA2AADORA1 | |
| SCHEMBL902067 | 0.74 | MTOR (0.54) | HRH4HTR3AKDM4ERAD52UBE2N | |
| SCHEMBL4110099 | 0.73 | ADORA2A (0.52) | KDM4EADORA2AADORA1 | |
| SCHEMBL4106909 | 0.73 | ALDH1A1 (0.57) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | claimed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-8338435-B2 | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | PNPO, PNP, DPYD | HRH4 1129/4885HTR3A 204/4885KDM4E 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.